MXPA02011780A - Producto de combinacion que incluye melagatran y un inhibidor de factor xa. - Google Patents

Producto de combinacion que incluye melagatran y un inhibidor de factor xa.

Info

Publication number
MXPA02011780A
MXPA02011780A MXPA02011780A MXPA02011780A MXPA02011780A MX PA02011780 A MXPA02011780 A MX PA02011780A MX PA02011780 A MXPA02011780 A MX PA02011780A MX PA02011780 A MXPA02011780 A MX PA02011780A MX PA02011780 A MXPA02011780 A MX PA02011780A
Authority
MX
Mexico
Prior art keywords
combination product
melagatran
inhibitor
factor
pharmaceutically
Prior art date
Application number
MXPA02011780A
Other languages
English (en)
Inventor
Christer Mattsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA02011780A publication Critical patent/MXPA02011780A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

Se provee un producto de combinacion que comprende: (A) melagatran o un derivado del mismo farmaceuticamente aceptable; y (B) un inhibidor de Factor Xa o un derivado del mismo farmaceuticamente aceptable, en el que cada uno de los componentes (A) y (B) esta formulado en combinacion con un coadyuvante, diluyente o excipiente farmaceuticamente aceptable, asi como el uso de dicho producto de combinacion en el tratamiento de una condicion en la que esta indicada la terapia anticoagulante.
MXPA02011780A 2000-06-10 2001-06-06 Producto de combinacion que incluye melagatran y un inhibidor de factor xa. MXPA02011780A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0014136.6A GB0014136D0 (en) 2000-06-10 2000-06-10 Combination therapy
PCT/SE2001/001288 WO2001095931A1 (en) 2000-06-10 2001-06-06 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR

Publications (1)

Publication Number Publication Date
MXPA02011780A true MXPA02011780A (es) 2003-04-10

Family

ID=9893354

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011780A MXPA02011780A (es) 2000-06-10 2001-06-06 Producto de combinacion que incluye melagatran y un inhibidor de factor xa.

Country Status (22)

Country Link
US (1) US20030158120A1 (es)
EP (1) EP1294394B1 (es)
JP (1) JP2004503508A (es)
KR (1) KR20030007939A (es)
CN (1) CN1431912A (es)
AT (1) ATE322908T1 (es)
AU (2) AU2001264494B2 (es)
BR (1) BR0111545A (es)
CA (1) CA2410100A1 (es)
CY (1) CY1105068T1 (es)
DE (1) DE60118732T2 (es)
DK (1) DK1294394T3 (es)
ES (1) ES2260225T3 (es)
GB (1) GB0014136D0 (es)
HK (1) HK1052463B (es)
IL (1) IL152897A0 (es)
MX (1) MXPA02011780A (es)
NO (1) NO20025909L (es)
NZ (1) NZ522866A (es)
PT (1) PT1294394E (es)
WO (1) WO2001095931A1 (es)
ZA (1) ZA200209487B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103590D0 (sv) 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
WO2007008145A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
CA2657269A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
US8790924B2 (en) 2006-10-19 2014-07-29 Duke University Reversible platelet inhibition
CA2825252C (en) 2011-01-25 2018-10-16 Universite Catholique De Louvain Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
JP6034406B2 (ja) * 2012-01-25 2016-11-30 ユニヴェルシテ カソリック ド ルーヴァンUniversite Catholique De Louvain 細胞移植のための組成物および方法
US20160129047A1 (en) 2013-07-05 2016-05-12 Université Catholique de Louvain Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
EP2843416A1 (de) * 2013-09-02 2015-03-04 Siemens Healthcare Diagnostics Products GmbH Kontroll- und Kalibratormaterial für die Bestimmung von direkten Antikoagulanzien
WO2016176426A1 (en) 2015-04-28 2016-11-03 Duke University Thrombus imaging aptamers and methods of using same
JP2019528739A (ja) 2016-09-16 2019-10-17 デューク ユニバーシティ フォン・ビルブラント因子(vwf)標的薬剤およびそれを用いる方法
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use

Also Published As

Publication number Publication date
ES2260225T3 (es) 2006-11-01
PT1294394E (pt) 2006-07-31
EP1294394B1 (en) 2006-04-12
AU6449401A (en) 2001-12-24
BR0111545A (pt) 2003-07-01
CA2410100A1 (en) 2001-12-20
DE60118732D1 (de) 2006-05-24
DE60118732T2 (de) 2006-10-05
GB0014136D0 (en) 2000-08-02
DK1294394T3 (da) 2006-07-10
ZA200209487B (en) 2004-02-23
WO2001095931A1 (en) 2001-12-20
HK1052463B (zh) 2006-10-13
CN1431912A (zh) 2003-07-23
JP2004503508A (ja) 2004-02-05
CY1105068T1 (el) 2010-03-03
NO20025909D0 (no) 2002-12-09
EP1294394A1 (en) 2003-03-26
KR20030007939A (ko) 2003-01-23
IL152897A0 (en) 2003-06-24
NO20025909L (no) 2003-02-07
US20030158120A1 (en) 2003-08-21
NZ522866A (en) 2004-09-24
AU2001264494B2 (en) 2006-01-05
ATE322908T1 (de) 2006-04-15
HK1052463A1 (en) 2003-09-19

Similar Documents

Publication Publication Date Title
CY1105068T1 (el) ΈΝΑ ΠΡΟΪΟΝ ΣΥΝΔΥΑΣΜΟΥ ΠΟΥ ΠEPΙΛΑΜΒΑΝΕΙ ΜΕΛΑΓΑΤΡΑΝΗ ΚΑΙ ΕΝΑΝ ΑΝΑΣΤΟΛΕΑ ΠΑΡΑΓΟΝΤΑ ΓΙΑ Xa
TW200505434A (en) Therapeutic treatment
MXPA03007140A (es) Derivados de carbolina.
AU2001266575A1 (en) Chemical compounds
DE60216233D1 (en) Carbolinderivate
MXPA02012076A (es) Compuestos quimicos.
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA03002911A (es) Compuestos quimicos.
CY1107343T1 (el) ΕΝΑ ΠΡΟΪΟΝ ΣΥΝΔΥΑΣΜΟΥ ΠΟΥ ΠEPΙΛΑΜΒΑΝΕΙ ΜΕΛΑΓΑΤΡΑΝΗ ΚΑΙ ΕΝΑΝ ΑΝΑΣΤΟΛΕΑ ΠΑΡΑΓΟΝΤΑ VIIa
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
GB0018951D0 (en) Novel compounds
PL377176A1 (pl) N-Sulfonylo-4-metylenoamino-3-hydroksy-2-pirydony
GB0027705D0 (en) Novel compounds
MXPA02012472A (es) Compuestos quimicos.
MXPA04003771A (es) Un producto de combinacion que comprende melagatran y dexametasona.
ATE342907T1 (de) Tumorhemmende lanthanverbindungen
WO2003033523A3 (en) Cytotoxic compounds

Legal Events

Date Code Title Description
FG Grant or registration